When to Add Anti-angiogenesis Drugs to EGFR-mutated Metastatic Non–small Cell Lung Cancer Patients

BMC Cancer

First-line combination EGFR-TKI plus anti-angiogenesis therapy improves PFS in patients with stage IV EGFR-mutant NSCLC. Adding an anti-angiogenesis drug at any line to patients harboring L858R mutation with pleural, liver, or bone metastases can provide survival benefits.